A new drug has been approved for the treatment of schizophrenia in adults. On Thursday, the U.S. Food and Drug Administration (FDA) approved COBENFY (xanomeline and trospium chloride), an oral medication that is manufactured by Bristol Myers Squibb in New Jersey. This marks the first new class of medications for the brain disorder in several…